Rising Biosciences (Rising Biosciences) Capital Expenditure : $0.00 Mil (TTM As of . 20)

View and export this data going back to . Start your Free Trial

What is Rising Biosciences Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Rising Biosciences's cash flow for capital expenditures for the three months ended in . 20 was $0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in . 20 was $0.00 Mil.

Rising Biosciences Capital Expenditure Historical Data

The historical data trend for Rising Biosciences's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rising Biosciences Capital Expenditure Chart

Rising Biosciences Annual Data

Trend

Capital Expenditure

Rising Biosciences Quarterly Data

Capital Expenditure

Rising Biosciences Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Rising Biosciences (Rising Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rising Biosciences Inc (GREY:RBII) » Definitions » Capital Expenditure

Traded in Other Exchanges

N/A

Address

1180 Cleveland Road, Sandusky, OH, USA, 44870

Website

http://www.risingbiosciences.com

Rising Biosciences Inc is a United States-based company engaged in research and development activities. It is focused on oral and topical cannabis and non-cannabis based pharmaceuticals. The company seeks to address the market demand for the treatment of the danger of opiates, whose long-term effects can include liver damage, addiction and brain damage due to hypoxia, resulting from respiratory depression, among other complications.